Metastatic Melanoma Clinical Trials in Pittsburgh, Pennsylvania

6 studies are recruiting for metastatic melanoma in Pittsburgh, Pennsylvania right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

   This phase II trial compares the effect of encorafenib, binimetinib, and nivolumab versus ipilimumab and nivolumab in treating patients with BRAF- V600 mutant melanoma that has spread to the brain (brain metastases). Encorafenib and binimetinib may stop the growth of tumor cells by blocking some of…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania

   Locations

   331 in total

   Run by

   SWOG Cancer Research Network

   See if you can join NCT04511013 on ClinicalTrials.gov

2. Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

   This phase II trial tests the combination of nivolumab and ipilimumab with sirolimus and prednisone for the treatment of skin (cutaneous) cancer that cannot be removed by surgery (unresectable) or that has spread from where it first started to other places in the body (metastatic) in kidney transpl…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

   Locations

   26 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05896839 on ClinicalTrials.gov

3. Safety and Efficacy of OBX-115 in Advanced Solid Tumors

   This is a study to investigate the safety and efficacy of an investigational OBX-115 regimen in adult participants with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Allegheny Research Institute (Melanoma/NSCLC), Pittsburgh, Pennsylvania

   Locations

   10 in total

   Run by

   Obsidian Therapeutics, Inc.

   See if you can join NCT06060613 on ClinicalTrials.gov

4. Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

   This is a Phase 3, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of lifileucel in combination with pembrolizumab compared with pembrolizumab alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to…

   Stage

   Phase 3

   Ages

   18 to 70

   Site

   Allegheny Health Network, Pittsburgh, Pennsylvania

   Locations

   81 in total

   Run by

   Iovance Biotherapeutics, Inc.

   See if you can join NCT05727904 on ClinicalTrials.gov

5. A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

   This is a study to investigate the efficacy and safety of an infusion of IOV-4001 in adult participants with unresectable or metastatic melanoma or advanced non-small-cell lung cancer (NSCLC).

   Stage

   Phase 1

   Ages

   18 to 70

   Site

   UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

   Locations

   11 in total

   Run by

   Iovance Biotherapeutics, Inc.

   See if you can join NCT05361174 on ClinicalTrials.gov

6. MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma

   In this first-in human, phase I/IIa study, the safety and efficacy of [212Pb]VMT01, an alpha-particle emitting therapeutic agent targeted to melanocortin sub-type 1 receptor (MC1R) is being evaluated as a monotherapy and in combination with nivolumab in subjects with unresectable and metastatic mel…

   Stage

   Phase 1

   Ages

   18 to 90

   Site

   UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

   Locations

   13 in total

   Run by

   Perspective Therapeutics

   See if you can join NCT05655312 on ClinicalTrials.gov